RecruitingPhase 1Phase 2NCT07136142

A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors

A Multicenter, Open Label Phase I/II Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of FH-006 for Injection in Patients With Malignant Solid Tumors

Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Enrollment

150 participants

Start Date

Sep 23, 2025

Study Type

INTERVENTIONAL

Conditions

Malignant Solid Tumor

Summary

This study aims to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of FH-006 in subjects with advanced malignant solid tumors, and determine the preliminary efficacy.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called FH-006 for Injection for people with malignant solid tumor. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFH-006 for Injection

FH-006 for injection.

Locations(2)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Tianjin Medical Unversity Cancer Institute & Hospital

Tianjin, Tianjin Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07136142

Related Trials

Personalized Neoantigen-pulsed Autologous Dendritic Cell Injections for Malignant Solid Tumors

NCT07752953

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

NCT0411654113 locations

ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu

NCT068243631 location

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

NCT0414562228 locations

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

NCT054683592 locations